Simvastatin combined with antiviral therapy for hepatitis B cirrhosis with portal hypertension - A case report

Sep 30, 2026

Uploaded by Kurz

Rationale: Clinical management of hepatitis B cirrhosis complicated with portal hypertension remains challenging. Nonselective beta-blockers such as carvedilol have limitations, and evidence for simvastatin—especially regarding hepatic venous pressure gradient (HVPG)—is scarce. This report evaluates simvastatin combined with antiviral therapy in patients intolerant to carvedilol. Patient concerns and interventions highlight bradycardia management by switching or restarting simvastatin with antiviral maintenance. Outcomes show effective portal pressure lowering without drug-related adverse reactions.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages5

Reading Time13 min

AccessFree to download

Abstract

Introduction

Case presentation

Case 1

® Clinical Case Report Simvastatin combined with antiviral therapy for hepatitis B cirrhosis with portal hypertension A case report Haodong Zhang, MDa , Jinjin Li, MDa , Yong Zhou, MDa , Xuefang Li, MDa , Hui Wang, MDa , Wei Gou, PhDa ,* , Zhensheng Liu, MDa , Xiaolong Qi, PhDb | Abstract
Rationale: Clinical management of hepatitis B cirrhosis complicated with portal hypertension remains challenging. nonselective beta-blockers like carvedilol, first-line agents, have notable limitations. While simvastatin may improve liver fibrosis and reduce portal hypertension, clinical evidence – especially regarding hepatic venous pressure gradient (HVPG)– is scarce. This study investigates the efficacy and safety of simvastatin combined with antiviral therapy in patients intolerant to carvedilol.
Patient concerns: Case 1: A 54-year-old male was admitted due to abnormal liver function for 2 weeks and fatigue with abdominal distension for 2 days. Vital signs were stable, with chronic liver disease facies, soft abdomen, positive hepatic percussion tenderness, no hepatosplenomegaly, and no ascites. Case 2: A 62-year-old male presented with intermittent fatigue for 3 months (aggravated for 1 week) . His pulse rate was 49 beats per minute with mild dizziness (no chest tightness/pain), accompanied by chronic liver disease facies, liver palms, soft abdomen, positive hepatic percussion tenderness, and no ascites or bleeding.
Diagnoses: Case 1: Compensated hepatitis B cirrhosis; Portal hypertension; Carvedilol-induced bradycardia. Case 2: Compensated hepatitis B cirrhosis; Portal hypertension; Sinus bradycardia.
Interventions: Basic treatment focused on HBV suppression, with portal hypertension management adjusted per contraindications and responses. Case 1 initially received carvedilol but switched to long-term simvastatin due to bradycardia. Case 2 was prescribed simvastatin upfront (given preexisting bradycardia); after self-discontinuing (HVPG increased), simvastatin was restarted for long-term maintenance.
Outcomes: Nucleoside analogues (antiviral) plus simvastatin (reducing intrahepatic vascular resistance) effectively lowered portal venous pressure without drug-related adverse reactions.
Lessons: For hepatitis B cirrhosis patients with portal hypertension who are intolerant to or have contraindications for carvedilol, simvastatin combined with antiviral therapy is a safe, effective alternative. It significantly reduces HVPG, improves liver stiffness, and causes no obvious adverse events.
Abbreviations: HVPG = hepatic venous pressure gradient, NSBBs = nonselective beta-blockers. | | --- | | Keywords: hepatic venous pressure gradient, hepatitis B cirrhosis, portal hypertension, simvastatin | 1. Introduction The management of portal hypertension in hepatitis B cirrhosis remains a clinical challenge. Although the Baveno VII consensus recommends nonselective beta-blockers (NSBBs) such as carvedilol as first-line options,[1] safety concerns with NSBBs persist in patients with refractory ascites or spontaneous bacterial peritonitis. [2] Additionally, patients with second- or third-degree atrioventricular block (without a pacemaker), asthma, or sinus bradycardia represent absolute contraindications for NSBB use,[3] posing significant clinical limitations. While emerging studies suggest simvastatin may have beneficial effects on liver fibrosis and portal hypertension,[4–6] limited clinical data are currently available. Here, we report two cases of hepatitis B-related cirrhotic portal hypertension effectively treated with the addition of simvastatin to antiviral therapy, in hopes of contributing to the research on pharmacological treatments for cirrhotic portal hypertension. HZ and JL contributed to this article equally. This work was supported by Qingdao Key Medical and Health Discipline Project. Written informed consent was obtained from the patient for the publication of this case report, including all clini

FAQs

Why is portal hypertension management in hepatitis B cirrhosis considered challenging?

Because available first-line options like nonselective beta-blockers (e.g., carvedilol) can have safety limitations, especially in patients with refractory ascites, spontaneous bacterial peritonitis, or specific contraindications such as bradycardia or conduction block.

What patient problems led to the use of simvastatin in these cases?

Case 1 involved carvedilol-induced bradycardia, prompting a switch to long-term simvastatin. Case 2 had preexisting sinus bradycardia, so simvastatin was used upfront; after treatment interruption led to HVPG increase, simvastatin was restarted.

What were the main outcomes of combining simvastatin with antiviral therapy?

Nucleoside analogues plus simvastatin lowered portal venous pressure effectively without drug-related adverse reactions, with reported benefits including reduced HVPG and improved liver stiffness.

Sep 30, 2026

Uploaded by Kurz